(137) of the cases returned negative results, 32% (44) of these patients were irrationally prescribed with anti-malarial drugs sans confirmed diagnosis with injectable artesunate (61%) and chloroquine (32%) for an average of 4 days resulting in 41% overdoses and 38% under doses. Direct cost associated was estimated to be USD 1,167.71. Female bedridden patients with fever and chills ≤ 3 days with normal hematological parameters, liver and renal function tests were more likely prescribed with anti-malarials. These patients had fewer co-morbidities, lower mortality, longer survival rate and longer hospitalization (p< 0.05). ConClusions: Through geriatric pharmaceutical care services, clinical pharmacist can reduce inappropriate prescribing and prevent possible adverse effects without hampering the health related quality of life.
first year and 0.19% five years later. ConClusions: The introduction of olaparib as maintenance treatment in the PSR BRCAm HGSOC patients has a manageable budget impact in Spain and suggest that it it could increase PFS and delay subsequent chemotherapy.
A401of which were hysterectomies. Before the launch of UPA in France, number of surgeries increased by 380 each year. The introduction of UPA was correlated with a trend reversal, showing a decrease in the number of surgeries of 1,236 each year from mid-2013. UPA did not have an impact on the type of surgery, neither on the surgical approach. The savings associated with the use of UPA pre-operatively (cost of treatment and avoided surgeries included) were estimated at 2M€ in 2013 and will reach 9M€ in 2016, that was considered as a plateau for the following years. The cumulated budgetary impact from 2016 to 2019 is estimated at -37M€ . ConClusions: Thanks to avoided surgeries, the use of UPA as pre-operative treatment is associated with financial savings, which cover largely the treatment costs. PIH10 Budget-ImPact analysIs (BIa) Of tHe IntrOductIOn Of 52mg levOnOrgestrel-releasIng IntrauterIne system (lng-Ius) as a cOntracePtIve metHOd OPtIOn In tHe BrazIlIan PuBlIc HealtHcare system (sus) tO avOId unIntended Pregnancy (uP) In 15 tO 19 year-Old adOlescents
Objectives: Topical growth factors accelerate wound healing in patients with diabetic foot ulcers (DFU). In the absence of head to head comparisons, we carried out a network meta-analysis comparing the efficacy and safety of growth factors. MethOds: Using an appropriate search strategy, randomized controlled trials on topical growth factors compared with standard of care in patients with DFU, were included. Odds ratio [95% confidence interval] was used as the effect estimate and random effects model was used for both direct and indirect comparisons. Markov Chain Monte Carlo simulation was used to obtain pooled estimates. Rankogram was generated based on surface under the cumulative ranking curve (SUCRA). Results: A total of 26 studies with 2088 participants and 1018 events were included. No inconsistency was observed. The pooled estimates for recombinant epidermal growth factor (rhEGF), autologous platelet rich plasma (PRP), recombinant human plateletderived growth factor (rhPDGF) were 5. 72 [3.34, 10.37], 2.65 [1.60, 4.54] and 1.97 [1.54, 2.55] respectively. SUCRA for rhEGF was 0.95. Sensitivity analyses did not have a significant effect on the pooled estimates and rankogram. No differences were observed in the overall risk of adverse events between the growth factors. cOnclusiOns: To conclude, rhEGF, rhPDGF and autologous PRP were found to significantly improve the healing rate when used as adjuvant to standard of care. Recombinant human epidermal growth factor may perform better than other growth factors.
A875 substantially higher objective response rates favouring patients receiving nivolumab (25.1% vs 5.4%; odds ratio: 5.98, P< 0.001) was observed in this trial. The aim of this analysis was to compare the monthly cost per responder with nivolumab versus everolimus in the Brazilian private healthcare system perspective. Methods: This analysis was based on investigator-based patient-level data from a randomized phase III trial. ORR was defined as the proportion of patients who achieved a partial or complete response. Costs were calculated based on drug, administration, and managing of grade 1-4 treatment related adverse events (TRAEs) reported on Checkmate 025. Drug costs for nivolumab and everolimus were obtained from the official Brazilian price list (Feb/2017) by CMED. The management of TRAEs was obtained through a Delphi panel, followed by microcosting of resources obtained from public sources (Kairos and Simpro Magazine n105/2016 for drugs and materials, CBHPM 2016 for medical appointments and procedures, and UNIDAS National Research 2015 for hospitalizations). Monthly cost per objective response was calculated by dividing the average monthly cost per patient by ORR. Results: Median duration of treatment was 5.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.